We are proud to announce that the Efferon LPS hemoadsorption device has received official marketing authorization from the Saudi Food and Drug Authority (SFDA) in the Kingdom of Saudi Arabia. Now it’s available in 32 countries worldwide.

Together with our partner ExpertsMed Trading Co. L.L.C., a company with strong expertise in emerging markets and a presence across more than 100 markets, we are committed to supporting and developing new regions to achieve sustainable, long-term growth.

Efferon LPS is a next-generation hemoadsorption device engineered to remove endotoxins and cytokines from the bloodstream. It is approved for use in sepsis patients under the EU MDR regulation and authorized by leading regulatory agencies, including MHRA (UK), HALMED (Croatia), and now SFDA (Saudi Arabia).